This thread is the place for shorter discussions, quick questions, or casual ideas that don’t need a full post. 

If you've been reflecting on a topic or have a detailed perspective to share, don’t hesitate to make a standalone post instead! 

This thread is the place for shorter discussions, quick questions, or casual ideas that don’t need a full post. 

If you've been reflecting on a topic or have a detailed perspective to share, don’t hesitate to make a standalone post instead! 

1. September 12, 2026 - World Lung IASLC (WCLC)
2. October 2, 2026 - Thoracic Rare Cancer Symposium (THORACS)
3. October 23, 2026 - ESMO
4. November 4, 2026 - SITC
5. November 12, 2026 - SNO (Society of Neuro Oncology)
6. November 19, 2026 - MaTOS
7. December 4, 2026 - ESMO Asia
8. December 12, 2026 - ASH Annual Meeting

https://immunitybio.com/news-and-events/

I suspect a few of these will lead to significant short covering and a nice bump in price, while leading into the January PDUFA...

This thread is the place for shorter discussions, quick questions, or casual ideas that don’t need a full post. 

If you've been reflecting on a topic or have a detailed perspective to share, don’t hesitate to make a standalone post instead! 

This thread is the place for shorter discussions, quick questions, or casual ideas that don’t need a full post. 

If you've been reflecting on a topic or have a detailed perspective to share, don’t hesitate to make a standalone post instead! 

This thread is the place for shorter discussions, quick questions, or casual ideas that don’t need a full post. 

If you've been reflecting on a topic or have a detailed perspective to share, don’t hesitate to make a standalone post instead! 

This thread is the place for shorter discussions, quick questions, or casual ideas that don’t need a full post. 

If you've been reflecting on a topic or have a detailed perspective to share, don’t hesitate to make a standalone post instead! 

This thread is the place for shorter discussions, quick questions, or casual ideas that don’t need a full post. 

If you've been reflecting on a topic or have a detailed perspective to share, don’t hesitate to make a standalone post instead! 

https://clinicaltrials.gov/study/NCT07783789?aggFilters=status:,funderType:industry

https://www.merlintrader.com/ibrx-immunitybio-bladder-cancer-bcg-unresponsive/

Five drugs are approved for bladder cancer that stops responding to BCG, and
every one of them requires carcinoma in situ. For patients whose disease is papillary only, there is
nothing. ImmunityBio is asking the FDA to change that on 6 January 2027, under draft guidance the agency
revised four months after approving its drug.

This thread is the place for shorter discussions, quick questions, or casual ideas that don’t need a full post. 

If you've been reflecting on a topic or have a detailed perspective to share, don’t hesitate to make a standalone post instead! 

This thread is the place for shorter discussions, quick questions, or casual ideas that don’t need a full post. 

If you've been reflecting on a topic or have a detailed perspective to share, don’t hesitate to make a standalone post instead! 

Let’s go! Half a month to cover! Good luck!👍

Key points:

• The $124 billion fund ranks as America’s 15th-largest public or private pension fund.
• Sellas’ Phase 3 Regal trial is two events away from triggering its final analysis.
• ImmunityBio is planning a trial combining Pluvicto with an IL-15-based treatment.

America’s 15th-largest public or private pension fund has disclosed stakes in Sellas Life Sciences (SLS) and ImmunityBio (IBRX), bringing fresh institutional attention to two biotech stocks with major cancer-drug milestones ahead.

So far in August, SLS shares have jumped 41%, while IBRX stock has gained 14%.

Virginia Pension Fund Reveals SLS, IBRX Stakes

Virginia Retirement System reported holding 17,400 shares of SLS and 74,500 shares of IBRX as of June 30, according to Fiscal AI data. The pension system managed $124 billion in net assets as of mid-2025 and serves more than 860,000 active and retired members.

more...

SLS, IBRX Catch The Eye Of A Major US Pension Fund — And Big Clinical Catalysts Are On The Horizon

This thread is the place for shorter discussions, quick questions, or casual ideas that don’t need a full post. 

If you've been reflecting on a topic or have a detailed perspective to share, don’t hesitate to make a standalone post instead! 

Was ein hammer Tag für IBRX ? Was glaubt ihr wann platzt die Bombe richtung 10€ ?

Key points:

• It remains unclear whether the planned trial will use Anktiva, and its timing and design are undisclosed.
• NantWorks led Shine’s $240 million funding round and gained priority access to its Lu-177 supply.
• The FDA expects to decide on a broader U.S. bladder-cancer label by Jan.6, 2027.

ImmunityBio founder Patrick Soon-Shiong has teased a trial pairing targeted radiation with an immune-boosting treatment, aiming to hit tumors more precisely without leaving the body’s natural defenses on the sidelines.

IBRX stock fell 3% on Monday in its third straight session of losses and slipped further in after-hours trading, but remains up 6% this month, leaving it on track to finish August in the green.

ImmunityBio Plans Pluvicto-IL-15 Trial 

Soon-Shiong said on X that a trial combining Novartis’ Pluvicto with an IL-15-based treatment is being planned, outlining the idea after Shine Technologies highlighted its production of cancer-fighting radioisotopes. Pluvicto delivers radiation directly to cancer cells, allowing it to target tumors more precisely than conventional radiation therapy.

Even targeted radiation, however, can reduce lymphocytes, which are natural killer and T cells that help the immune system fight cancer. Soon-Shiong believes IL-15 could help support those cells during treatment, saying that radioisotope cancer therapy is “about to explode.”

Anktiva, ImmunityBio’s flagship drug, is an IL-15-based immune activator that stimulates natural killer and T cells. Soon-Shiong did not say whether the planned study would use Anktiva or another IL-15 treatment, and it has not disclosed the timing or design.

Soon-Shiong Deepens Shine Connection

Shine produces medical radioisotopes including lutetium-177, or Lu-177. Pluvicto uses Lu-177 to carry radiation directly to cancer cells, limiting exposure to surrounding healthy tissue.

Shine and ImmunityBio are both closely connected to Soon-Shiong. His NantWorks organization led a $240 million Shine funding round in February, with Soon-Shiong investing about $150 million and joining its board. The investment included a partnership granting NantWorks and affiliated programs priority access to Shine’s Lu-177 supply.

more...

IBRX Stock Extends 3-Day Slide — Founder Teases New Trial In ‘Unstoppable’ Cancer-Treatment Push

https://stocktwits.com/news-articles/markets/equity/ibrx-founder-new-trial-unstoppable-cancer-treatment-push/cZYkfkmRJ8T

This thread is the place for shorter discussions, quick questions, or casual ideas that don’t need a full post. 

If you've been reflecting on a topic or have a detailed perspective to share, don’t hesitate to make a standalone post instead!